How a Google DeepMind Spinoff Hunts Hidden Drug Targets (opens in new tab)

drug discovery. Yet despite billions of dollars in investment, relatively few AI-designed medicines have made it to patients. That’s partially because the timelines for careful drug testing can’t be easily compressed—and partially because drug development is just really hard. Isomorphic Labs, the Google DeepMind spinout that’s building on DeepMind’s Nobel Prize-winning work on protein structure prediction, may be making the most progress. The company has signed major drug-discovery partnershi...